Emergent BioSolutions (EBS) Scheduled to Post Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS) will be releasing its earnings data after the market closes on Wednesday, May 1st. Analysts expect Emergent BioSolutions to post earnings of ($3.65) per share for the quarter. Emergent BioSolutions has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS) last issued its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.44). Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. The company had revenue of $276.60 million during the quarter, compared to analyst estimates of $247.63 million. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. On average, analysts expect Emergent BioSolutions to post $-14 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Emergent BioSolutions Stock Down 1.5 %

Shares of EBS stock opened at $1.92 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.54 and a current ratio of 1.04. The business has a 50 day moving average of $2.45 and a two-hundred day moving average of $2.23. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $10.88.

Wall Street Analyst Weigh In

Separately, Benchmark restated a “buy” rating and issued a $5.00 target price on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.